Real-life efficacy and toxicity of lutetium peptide receptor radionuclide therapy in patients with progressive, metastatic neuroendocrine tumors who failed at least one line of systemic treatment

被引：0
作者：
Kavan, P. [1 ]
Rho, H. [1 ]
Probst, S. [2 ]
Abikhzer, G. [2 ]
Rho, Y. S. [3 ]
Barrera, I [1 ]
机构：
[1] McGill Univ, Segal Canc Ctr, Dept Med Oncol, Montreal, PQ, Canada
[2] Jewish Gen Hosp, Div Nucl Med, Montreal, PQ, Canada
[3] Univ Hawaii, John A Burns Sch Med, Honolulu, HI USA
来源：
JOURNAL OF NEUROENDOCRINOLOGY | 2023年 / 35卷
关键词：
neuroendocrine tumor; lutetium; prrt; efficacy; safety;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
H21
引用
收藏
页码：193 / 193
页数：1
相关论文
共 43 条
[1]   Real-world efficacy of lutetium peptide receptor radionuclide therapy in patients with neuroendocrine tumors [J].
Almeamar, H. ;
Cullen, L. ;
Murphy, D. ;
Crowley, R. ;
Skehan, S. ;
Welin, S. ;
O'Shea, D. ;
O'Toole, D. .
JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 :136-136
[2]   Real-world efficacy of lutetium peptide receptor radionuclide therapy in patients with neuroendocrine tumours [J].
Almeamar, Hussein ;
Cullen, Lisa ;
Murphy, David J. ;
Crowley, Rachel K. ;
Toumpanakis, Christos ;
Welin, Staffan ;
O'Shea, Donal ;
O'Toole, Dermot .
JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 (06)
[3]   Peptide receptor radionuclide therapy for treatment of metastatic neuroendocrine tumors in children [J].
Foster, Jennifer H. ;
Sher, Andrew ;
Seghers, Victor ;
Poston, Jay ;
Wells, Donald ;
Delpassand, Ebrahim S. ;
Potter, Samara ;
Mahajan, Priya ;
Venkatramani, Rajkumar .
PEDIATRIC BLOOD & CANCER, 2021, 68 (07)
[4]   Overall outcome of peptide receptor radionuclide therapy (PRRT) in treatment metastatic progressive neuroendocrine tumors (NETs): Survival, toxicity and prognostic factors [J].
Alsadik, S. R. ;
Gnanasegaran, G. ;
Chen, L. ;
Toumpanakis, C. ;
Caplin, M. ;
Navalkissoor, S. .
JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 :171-171
[5]   Peptide Receptor Radionuclide Therapy versus Capecitabine/Temozolomide for the Treatment of Metastatic Pancreatic Neuroendocrine Tumors [J].
Gujarathi, Rushabh ;
Tobias, Joseph ;
Abou Azar, Sara ;
Keutgen, Xavier M. ;
Liao, Chih-Yi .
CANCERS, 2024, 16 (17)
[6]   Peptide Receptor Radionuclide Therapy for Progressive and Metastatic Neuroendocrine Tumors: Analysis of Efficacy in 1,000 Patients from a Single Center [J].
Baum, R. P. ;
Kulkarni, H. ;
Zachert, C. ;
Kaemmerer, D. ;
Petrovitch, A. ;
Niepsch, K. ;
Hommann, M. ;
Hoersch, D. .
NEUROENDOCRINOLOGY, 2014, 99 (3-4) :282-282
[7]   Salvage peptide receptor radionuclide therapy in patients with progressive neuroendocrine tumors: a systematic review and meta-analysis [J].
Kim, Yong-il .
NUCLEAR MEDICINE COMMUNICATIONS, 2021, 42 (04) :451-458
[8]   Efficacy of 177Lu Peptide Receptor Radionuclide Therapy for the Treatment of Neuroendocrine Tumors A Meta-analysis [J].
Saravana-Bawan, Bianka ;
Bajwa, Amandeep ;
Paterson, John ;
McEwan, Alexander J. B. ;
McMullen, Todd P. W. .
CLINICAL NUCLEAR MEDICINE, 2019, 44 (09) :719-727
[9]   Safety and Efficacy of Peptide Receptor Radionuclide Therapy (PRRT) Following Bland Embolization for Metastatic Neuroendocrine Tumors [J].
Alayli, Adam ;
Ngo, Hoang ;
Sikaria, Dhiraj ;
Ahmed, Altan ;
Salloum, Elias ;
Strosberg, Jonathan R. ;
Al-Toubah, Taymeyah E. ;
Kis, Bela ;
Haider, Mintallah ;
El-Haddad, Ghassan .
CANCERS, 2024, 16 (15)
[10]   Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors [J].
Jiang, Yuanyuan ;
Liu, Qingxing ;
Wang, Guochang ;
Sui, Huimin ;
Wang, Rongxi ;
Wang, Jiarou ;
Zhang, Jingjing ;
Zhu, Zhaohui ;
Chen, Xiaoyuan .
THERANOSTICS, 2022, 12 (15) :6437-6445
12345